Abstract:Sitagliptin is an inhibitor of the enzyme dipeptidyl peptidase-4, used for the treatment of type 2 diabetes mellitus. The crystal structure of active pharmaceutical solids determines their physical and chemical properties. The polymorphism, solvates and hydrates can influence the free energy, thermodynamic parameters, solubility, solid-state stability, processability and dissolution rate, besides directly affecting the bioavailability. Thus, the physicochemical characterization of an active pharmaceutical ingredient is required to guarantee the rational development of new dosage forms. In this context, we describe herein the solid-state characterization of three crystalline forms of sitagliptin: sitagliptin phosphate monohydrate, sitagliptin phosphate anhydrous and sitagliptin base form. The investigation was carried out using differential scanning calorimetry (DSC), thermogravimetry (TG)/derivative thermogravimetry (DTG), spectroscopic techniques, X-ray powder diffraction (XRPD) and morphological analysis by scanning electron microscopy. The thermal analysis revealed that during the dehydration of sitagliptin phosphate monohydrate (Tpeak = 134.43 °C, ΔH = −1.15 J g−1) there is a characteristic crystalline transition event, which alters the physicochemical parameters of the drug, such as the melting point and solubility. The crystalline behavior of sitagliptin base form differs from that of sitagliptin phosphate monohydrate and sitagliptin phosphate anhydrous, mainly with regard to the lower temperature of the fusion event. The melting point (Tpeak) values obtained were 120.29 °C for sitagliptin base form, 206.37 °C for sitagliptin phosphate monohydrate and 214.92 °C for sitagliptin phosphate anhydrous. In relation to the thermal stability, sitagliptin phosphate monohydrate and sitagliptin phosphate anhydrous showed a slight difference; however, both are more thermostable than the base molecule. Therefore, through this study it was possible to establish the most suitable crystalline form of sitagliptin for the development of a safe, effective and appropriate pharmaceutical dosage form.

Synthesis of Sitagliptin Phosphate

Improved Synthetic Approach to Tenatoprazole

New Synthetic Method of Pioglitazone Hydrochloride

Synthesis of 2-mercapto-5-methoxyimidazo[4,5-b] pyridine

Improved Synthesis of 1-[Hexahydrocyclopenta[c]pyrrol-2(1h)-yl]-3-(4-methylbenzenesulfonyl)ure A

Enantioselective Synthesis of ( R )-Sitagliptin via Phase-Transfer Catalytic aza-Michael Addition

Synthesis of Quetiapine Hemifumarate

Electrochemical Synthesis of a Sitagliptin Precursor

Synthesis of 6-Aryl-3-(d-glucopentitol-1-yl)-7h-1,2,4-triazolo-[3,4-b][1,3,4]thiadiaz Ines

Synthesis of p-(Trifluoromethyl)thiobenzamide

Substrate Screening of Amino Transaminase for the Synthesis of A Sitagliptin Intermediate

Synthesis of Dapagliflozin

SYNTHESIS OF TICLOPIDINE HYDROCHLORIDE

Solid-State Characterization of Different Crystalline Forms of Sitagliptin

New Synthesis Process for the Synthesis of Ezetimibe

Synthesis and Biological Evaluation of Novel Benzyl-Substituted (S)-Phenylalanine Derivatives As Potent Dipeptidyl Peptidase 4 Inhibitors.

THE SYNTHESIS OF 1-SULFOMETHYLTETRAZOLE-5-THIOL DISODIUM SALT

A novel self-sufficient biocatalyst based on transaminase and pyridoxal 5'-phosphate covalent co-immobilization and its application in continuous biosynthesis of sitagliptin.

Synthesis of a New Antihyperlipidaemic Agent-Simvastatin

Synthesis of 5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methylpyrazole-3-carboxylic Acid

Synthesis of antitumor agent sunitinib malate